Skip to content
Biodatica
Start free

Beijing Pearl Biotechnology Limited Liability Company

Guangzhou, Guangdong

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

6w agoTrial registeredJun 5, 2026Source filing (opens the source filing in a new tab)

Momentum

83no change

Momentum 83 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

650 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 7, 2025

    Non-Small Cell Lung Cancer · RECRUITING · sponsor: Beijing Pearl Biotechnology Limited Liability Company · A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

    ClinicalTrials.gov · NCT06930794 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Oct 16, 2023

    Non-small Cell Lung Cancer · RECRUITING · sponsor: Beijing Pearl Biotechnology Limited Liability Company · A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

    ClinicalTrials.gov · NCT05989542 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jan 17, 2020

    Non-small Cell Lung Cancer · COMPLETED · sponsor: Beijing Pearl Biotechnology Limited Liability Company · A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

    ClinicalTrials.gov · NCT04258033 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources